SLC16A1 and neoplasm: MCT-1 inhibition leads to the accumulation of intracellular lactate, decreased tumour cell growth, a slower rate of glycolysis, and lower intracellular concentrations of ATP, NADPH, and the tripeptide antioxidant glutathione (GSH) [28].